- Home
- PHGE vs XAIR Comparison
PHGE vs XAIR Comparison
Compare PHGE & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHGE | XAIR |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | United States |
| Employees | 57 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2M | 10.1M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | PHGE | XAIR |
|---|---|---|
| Price | $4.96 | $0.80 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 64.3K | ★ 183.7K |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.09 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,705,000.00 |
| Revenue This Year | N/A | $122.00 |
| Revenue Next Year | N/A | $58.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 219.67 |
| 52 Week Low | $0.25 | $0.15 |
| 52 Week High | $8.50 | $3.78 |
Technical Indicators
Market Signals| Indicator | PHGE | XAIR |
|---|---|---|
| Relative Strength Index (RSI) | 46.18 | 36.58 |
| Support Level | $0.41 | $0.76 |
| Resistance Level | $6.28 | $1.25 |
| Average True Range (ATR) | 1.03 | 0.07 |
| MACD | -0.11 | 0.00 |
| Stochastic Oscillator | 25.41 | 22.63 |
Price Performance
Historical ComparisonAbout PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).
About XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.